Genmab — December 2017
-
Danske Bank har lavet en ny Genmab analyse i dag
-
De fastholder anbefaling og kursmål
-
Hvad er deres kursmål på Genmab?
-
nik, det er 1620 og Buy
-
Danske: Darzalex sales outlook not at risk. We still see no material changes to the future
combination treatment regimen, which includes daratumumab as one of the key
backbone therapies -
Danske: The market seems to be overwhelmed by the impressive
BCMA CAR T response rates compared to daratumumab monotherapy but
overlooks the immunomodulatory effects, which is believed to lead to the I/O-like
survival tailing effects. -
Danske: We continue to believe BCMA will act as a strong partner to
combination therapy with daratumumab to increase direct anti-tumour effects and
not a competitor that could potentially limit the use of daratumumab. -
Se se måske ligefrem sikre salg af Dara ?
-
E L, No only for customers
-
Nordea: Korrigeret for antal salgsdage steg salget med 7%, hvilket er en acceleration sammenlignet med de seneste måneders salg. Selv med en flad vækst i december ventes salget at nå vores estimater.
-
Nordea: Vi vurderer således, at Genmab er godt på vej til at indfri egne salgsmål for helåret på USD 1,2-1,3 mia., hvor vores estimater er på USD 1,25. Vi venter, at aktien går en god dag i møde og ser det seneste kursfald som en god langsigtet købsmulighed.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind